Despite FDA approval for Symvess having been secured, HUMA stock plummeted over 25% amid claims of pressured approval and potential safety risks, casting doubt on Symvess's market viability.

A former U.S. FDA employee said he and other agency reviewers were pressured to approve Humacyte's (NASDAQ:HUMA) Symvess, an artificial blood vessel, despite safety concerns. The implantable ...

Anthony Weiner's ex-wife Huma Abedin, 48, stiffed her former partner by giving him a lowball contribution of $175 for his comeback campaign for City Council. Paul Martinka Huma Abedin stiffed ex ...

HUMACYTE ($HUMA) is expected to release its quarterly earnings data on Friday, March 21st after market close, per Finnhub. Analysts are expecting revenue of $218,575 ...